Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Drug Allergy Seong H. Cho, MD Assistant Professor of Medicine Division of Allergy and Immunology Northwestern University Feinberg School of Medicine 경희의대 내과 전임 IS 교수 Allergy-Immunology Primary immunodeficiency (ex. CVID) Angioedema and urticaria Immunologic lung disease (ex. ABPA, hypersensitivity pneumonitis) Eosinophilc GI disorders (ex.EoE) Hypereosinophilc syndrome Mastocytosis Classification of Drug Reactions • Type A reactions (Most common) 1. Predictable 2. Related to pharmacologic actions of the drug 3. No specific host factors Type A Reactions • • • • Toxicity - Renal failure from aminoglycosides Side effect - Sedation from antihistamines Secondary effect - Diarrhea from antibiotics Drug Interaction - Theophylline toxicity from concomitant erythromycin Type B Reactions • Unpredictable • Less Common • Occur in susceptible individuals Type B Reactions • Intolerance - Tinnitus with aspirin • Idiosyncratic reaction - Hemolysis with dapsone in G6PD deficiency • Hypersensitivity (Specific immunologic) Anaphylaxis after penicillin • Pseudoallergic (non-immunologic) Anaphylactoid reaction to radiocontrast media Gell & Coombs Classification • Type I - Immediate hypersensitivity (IgEmediated) • Type II - Cytotoxic reactions • Type III - Immune complex (e.g. serum sickness, drug fever) • Type IV - Delayed hypersensitivity Sub classification of Type IV Reactions Pichler W. Ann Intern Med 2003;139:683-9. Other Immunopathology of Drug Reactions • Pseudoallergic reactions - Resemble type I reactions - Due to non-IgE-mediated mast cell activation - Examples: Opiates, vancomycin, radiocontrast media, NSAID-urticaria - Clinical importance: can be prevented by steroid • Innate Immune Reactions - Complement activation - Bradykinin release • Others (TEN/SJS/DRESS) Hapten Hypothesis • Haptens are chemically reactive small molecules • Undergo stable covalent binding to a larger protein or peptide • Covalent binding of small hapten drugs to selfproteins leads to immunogenic compounds • Penicillin classic example Prohapten Hypothesis • Drug that is not chemically reactive becomes reactive after metabolism • Chemically reactive drug metabolite can then bind covalently to proteins/peptides and become immunogenic • Sulfamethoxazole example: Metabolized to sulfamethoxazole-nitroso (highly reactive) • Others: Acetaminophen, phenytoin, procainamide, halothane Drug Presentation to T cells Posadas SJ et al. Clin Exp Allergy 2007;37:989–999 Risk Factors for Drug Allergy • Drug Related - Higher dose - Parenteral administration - Large molecular weight agents • Host Factors - Female gender - Age (less frequent in infants and elderly) - Diseases requiring repeated courses of therapy - Genetics Risk Factors for Drug Allergy • Atopy (allergy) - Atopy NOT a risk factor for small MW agents (e.g. beta-lactam allergy) - Atopy is a risk factor for: Latex allergy Radiocontrast media reactions Severe iv penicillin anaphylaxis Clinical Manifestation: Exanthems • Most common cutaneous drug eruption • Usually develops days after new medicine • Typically described as morbilliform “maculopapular” • Immunopathogenesis :Many T cell mediated Fixed Drug Eruptions • Mechanism unknown • Typically develops 1-2 weeks for initial reaction but sooner with later exposures • Occur in same location with each subsequent exposure to drug • Pleomorphic: Eczema, erythematous papules, hyperpigmented areas, bullous, urticarial • Examples: Tetracycline, NSAIDs, carbamazepime Photoallergic Reactions • Immune mediated: DTH reactions • UV light alters drug: Conjugation to selfprotein • Acute reactions usually 24-72 hrs • Medications: Quinidine, dapsone, HCTZ Phototoxic Reactions • Non-immunologic • No drug alteration by UV light • Erythroderma minutes to hrs after light exposure : Vesicles with severe reactions • Often with first exposure to drug • Medications: Sulfonamides, tetracycline, furosemide, HCTZ, fluoroquinolones Drug-Induced Blistering Disorders • Drug-Induced Pemphigus - 80% due to thiol group-containing medication : Captopril, penicillamine - Flaccid blisters • Drug-Induced Bullous Pemphigoid - Tense bullae on extremities, trunk, and sometime mucous membranes - ACE-I, furosemide, penicillin, sulfasalazine Linear IgA Bullous Dermatosis • Most commonly with vancomycin • Other medications : Captopril, furosemide, lithium, TMP/SMX • Tense blisters that mimic bullous pemphigoid • Generally occurs within 24 hours to 15 days following administration of the offending drug • Vancomycin-induced LAD is not dose dependent and the severity of the reaction does not correlate with serum vancomycin levels Systemic vs. Cutaneous Drug-Induced Lupus Erythematosis (DILE) Solensky R et al. Ann Allergy Asthma Immunol 2010;105:273e1-78. Serum Sickness • Mediated by immune complexes: Heterologous antisera, snake antivenom, Rabbit antithymocyte globulin (ATG) and rituximab • Clinical features: Fever, lymphadenopathy, arthralgias, rashes, gastrointestinal symptoms, proteinuria (some cases) • Typically occurs after 1-3 weeks: More rapidly in previously sensitized Serum Sickness-Like Reactions • Small molecular weight agents: Penicillin, sulfonamides, thiouracils, phenytoin • May lack features of immune complexes, hypocomplementemia, vasculitis, renal disease • Cefaclor most common cause in children - Altered metabolism leading to toxic reactive intermediates Drug Fever • Caused by release of pyrogens from phagocytes : - can be immune complex or T cell-mediated. • Typically 7-10 days after therapy • Fever pattern variable • Relieved within 48 hrs of stopping drug Pulmonary Drug Hypersensitivity • Pulmonary infiltrate with eosinophilia (PIE) - Cough within 10 days of starting drug - Migratory infiltrates - Peripheral eosinophilia - Antibiotics, NSAIDs most common cause of PIE - Nitrofurantoin most common antibiotic Pulmonary Drug Hypersensitivity • Amiodarone - Pneumonitis, bronchioloitis obliterans, ARDS - Some reactions may be immunologic • Methotrexate: Acute granulomatous ILD • Chemotherapeutics - ILD from bleomycin, mitomycin-C, busulfan, cyclophosphamide, nirosourea • Nitrofurantoin: Pleural effusion, pneumonitis, fibrosis Misc. Drug Allergy Syndromes • Immunologic nephropathy - Interstitial nephritis: +Urine eosinophils, benzyl penicillin, methicillin or sulfonamides - Membranous glomerulonephritis: gold, penicillamine, allopurinol • Aseptic meningitis: NSAID’s, IVIG, antibiotics • Immunologic hepatitis: Halothane, para-aminosalacylic acid, sulfonamides and phenothiazines Severe Cutaneous Adverse Reactions (SCAR) • AGEP • DRESS • SJS/TEN Acute Generalized Eczematous Pustulosis (AGEP) • Characterized by fine pustules, fever, and neutrophilia • Rash begins in intertriginous areas or face as edema and erythema Nonfollicular sterile pustules develop afterwards • Atypical target lesions, blisters and oral mucosal involvement uncommon but may confuse with SJS or TEN • Lesional T cells secrete high amounts of IL-8 (CXCL8) DRESS • Drug Rash Eosinophilia Systemic Symptoms • Causative Drugs : Anticonvulsants, sulfonamides, allopurinol, minocycline, dapsone, sulfasalazine, abacavir, nevirapine, hydroxychloroquine, vancomycin, etc. Clinical Features of DRESS (I) • Rash : Exanthem, erythroderma, erythema multiforme, purpura • Facial edema is diffuse and may be mistaken for angioedema - Genital & extremity edema • Fever : Vast majority of cases • Hypotension : Up to 40% cases Clinical Features of DRESS (II) • Hematologic abnormalities - Eosinophilia in > 50% - Anemia, neutropenia, thrombocytopenia/cytosis less common • Hypogammaglobulinemia in some cases Organ Involvement in DRESS • Lymphadenopathy <30% cases • Liver involvement in >60% cases • Renal dysfunction < 30% cases : 40-80% with allopurinol • Respiratory & Cardiac less common : Eosinophilic pneumonitis, cough, dyspnea, pharyngitis, Pericarditis, myocarditis Unique Aspects of DRESS • Reaction occurs after 2-8 weeks of therapy • Symptoms may worsen after drug discontinued • Symptoms may last weeks to even months after drug discontinued Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) • SJS/TEN thought to represent a spectrum of a single reaction • SJS: < 10% total body surface area Overlap SJS/TEN: 10-30% body surface area TEN: >30% surface area involvement SJS vs TEN *Nikolsky’s sign Clinical Features of SJS/TEN • Triad 1. Mucous membrane erosions: lip, oral cavity, conjunctiva, nasal cavity, urethra, and vagina 2. Target lesions 3. Epidermal necrosis with detachment • Multi-organ involvement - Gastrointestinal, hepatic, pulmonary, renal • Mortality: SJS: < 5%; TEN: 10-50% or higher SJS/TEN • Higher Risk Patients : HIV, SLE, Bone marrow transplant • High risk agents (*newer agents) : *Nevirapine, *lamotrigine, *sertraline, *pantoprazole, *tramadol, carbamazepime, phenytoin, phenobarbitol, sulfasalazine, allopurinol, sulfonamide antibiotics, oxicamNSAID’s • TEN usually drug-induced and glucocorticoids are contraindicated Penicillin Allergy (Antigens) • Major determinant (BPO) : 95% PCN reacts with self-proteins via beta-lactam ring to form benzylpenicilloyl (BPO) • Minor determinants - penicilloate - penilloate - penicillin G Penicillin Allergy • 90% patients with a Hx of PCN allergy will tolerate PCN • ~ 80% PCN allergic patients lose PCN IgE after 10 years • 1/3 patients with vague Hx of PCN allergy are PCN skin test positive PCN Skin Tests • Negative predictive value for anaphylaxis is close to 100% if skin test negative to penicilloylpolylysine (Pre Pen) and minor determinants • 10-20% of PCN-allergic patients show skin test reactivity only to penicilloate or penilloate : Clinical significance is unknown Ampicillin/Amoxicillin • Some patients have IgE antibodies directed at the Rgroup side chain (not core penicillin determinants) and are able to tolerate other penicillin class compounds - Frequent in Europe, rare in U.S. - PCN skin tests negative • Amoxicillin and ampicillin are associated with the development of a delayed maculopapular rash in about 5-10% of patients - not IgE-mediated - Concomitant conditions : EBV (infectious mono; ~100% children develop rash) Penicillin and Cephalosporins Share a common beta-lactam ring Cephalosporin & PCN Allergy • Only 2% of penicillin skin test-positive patients react to treatment with cephalosporins: Some fatal • If penicillin skin testing is unavailable, and cephalosporin needed, it may be given via graded challenge : Negative cephalosporin skin test appears to predict tolerance (Romano 2004) • Patients with a history of non-severe reaction to penicillin rarely react to cephalosporins Cephalosporin Allergy • Most hypersensitivity reactions to cephalosporins are directed at the R group side chains rather than the beta-lactam group • Cephalosporin allergic patients should avoid cephalosporins with similar R-group side chains PCN Allergy and Monobactams • Aztreonam (monobactam) does not crossreact with other beta-lactams : except for ceftazidime shares an identical R-group side chain PCN Allergy and Carbapenems • Moderate allergic cross-reactivity between penicillin and carbapenems based on skin tests : 50% PCN-allergic patients skin test positive to imipenem (Saxon 1988) • Clinical cross-reactivity variable but much lower - Recent studies suggest 0-11% react NEJM 2006;354:2835-7, Ann Intern Med 2007;146:266-69, JACI 2009;124:167-9. Skin testing for Non-PCN Antibiotics • There are no validated diagnostic tests for evaluation of IgE-mediated allergy to nonpenicillin antibiotics • A negative skin test result does not rule out the possibility of an immediate-type allergy • Positive skin test results to a drug concentration known to be non-irritating suggests the presence of drug-specific IgE Sulfonamide Allergy • A sulfonamide is any compound that contains a sulfonamide (SO2NH2) moiety • Sulfonamide antimicrobial drugs are different from other sulfonamide-containing medications (furosemide, thiazide diuretics and celecoxib) by virtue of an aromatic amine at the N4 position and a substituted ring at the N1 position Sulfonamide Allergy • Delayed maculopapular eruption most typical reaction: Mechanism unclear • Very frequent in HIV infected patients : (44-70%) Cross-Reactivity between Sulfonamide Antibiotics and Nonantibiotics • Myth about cross-reactivity between sulfonamide antibiotics and nonantibiotic drugs (lasix, HCTZ, sulfasalazine etc) • Patients with sulfonamide antibiotic allergy were more likely to react to penicillin than a sulfonamide non-antibiotic Strom BL et al. NEJM 2003;349:1628-35 Vancomycin: Red Man Syndrome • Constellation of symptoms - Pruritus, flushing, erythroderma common - Hypotension uncommon • Due to nonspecific histamine release that is rate related (rare reports of IgE-anaphylaxis) • Severity correlates with amount of histamine released into plasma • Severity reduced by - reducing rate to < 500 mg/hr - premedication with H1-antagonists Perioperative Drug Reactions • Neuromuscular blocking agents are most common (succinylcholine, rocuronium, atracurium, vecuronium, etc) - IgE mediated or direct mast cell activation • Other causes of IgE mediated perioperative reactions - Latex, barbiturates (thiopental), antibiotics Perioperative Drug Reactions • Dextran and hydroxyethyl starch : Anaphylactoid reactions • Propofol - Rare reports including those with egg allergy - Propofol contains egg lecithin (from egg yolk) which contains minimal contaminant egg protein - One study showed 98% egg allergic children tolerated propofol Chemotherapeutics • Taxanes (paclitaxel, docetaxel) - Anaphylactoid reactions - Pretreatment with systemic corticosteroids and antihistamines prevents most reactions • Platinum compounds (cisplatin, carboplatin, oxiplatin) - IgE mediated - typically cause hypersensitivity reactions after completion of several treatment courses • Asparaginase may cause anaphylactic or anaphylactoid reactions Local Anesthetic Allergy • Most adverse reactions to local anesthetics are due to nonallergic factors - Vasovagal, anxiety - Toxic or idiosyncratic reactions due to intravenous epinephrine • Local anesthetic groups - group 1 benzoic acid esters: procaine, benzocaine - group 2 amides: lidocaine, bupivicaine, mepivacaine • Based on patch testing, benzoic acid esters cross-react with each other, but not group 2 amide drugs Local Anesthetic Allergy • Skin tests are not adequate to diagnose lidocaine allergy : false positives • Graded challenge test of choice for evaluating potential local anesthetic allergy Radiocontrast Media Reactions • Mechanisms - Anaphylactoid : Direct mast cell activation ? IgE mediated (Allergy. 2009 Feb;64(2):234-41.) - Delayed reactions due to type IV hypersensitivity • Reaction rate from ionic contrast > non-ionic contrast • No evidence that sensitivity to seafood or iodine predisposes or is cross-reactive with RCM reactions Radiocontrast Anaphylactoid Reactions • Risk Factors - Female - Asthma - Cardiovascular disease - Prior reaction to RCM • Management - Non-ionic RCM - *Pre-treatment 1. Prednisone 50 mg : 13, 7, 1 hr prior 2. Diphenhydramine 50 mg : 1 hr prior 3. Ephedrine/albuterol 4. H2-antagonists : controversial *Pre-treatment does not completely prevent RCM reactions Aspirin-Exacerbated Respiratory Disease (AERD) • Associated with asthma, rhinitis, sinusitis, nasal polyposis • Symptoms with NSAIDs : Rhinorrhea, conjunctivitis, bronchospasm - Rarely flushing, urticaria, GI symptoms, laryngospasm, hypotension • Dependent on COX-1 inhibition • COX-2 inhibitors generally safe Pathophysiology of AERD - Inhibition of COX-1 results in : Inhibits PGE2 leading to ↑ leukotrienes - ↑ urinary LTE4 ↑ LTE4 and TXB2 in BAL ↑ LTC4 synthase expression in bronchial mucosa ↓ lipoxin generation ↑ cysLTR1 & cysLTR2 receptor expression ↑ response to inhaled LTD4 AERD • Diagnosis : Oral challenge Inhalation of lysine-ASA • Aspirin Desensitization - Improvement in upper and lower airway symptoms - After ASA desensitization ↓ uLTE4, ↓ BHR to LTE4 ↓ serum tryptase/histamine ↓ nasal expression of cysLT1 receptor Angiotensin Converting Enzyme (ACE) Inhibitors • Cough - Incidence up to 20% - Mechanism unknown - Angiotensin II receptor blockers (ARBs) tolerated • Angioedema - 0.1-0.7%, more common in African-Americans - Usually delayed in onset: mean 1.8 yrs (Malde 2007) - Likely des-Arg bradykinin induced - Usually tolerate ARBs but case reports of AE with ARBs too Insulin • Local Reactions - IgE mediated - Resolve with continued administration • Systemic Reactions - Usually occur after gap in insulin therapy (ex. Gestational diabetes) - Skin tests and desensitization may be required if insulin therapy interrupted > 24-48 hrs Adverse Reactions to Biologics • Cytokine release syndrome - Fever, rash, bronchospasm, capillary leak syndrome, GI sxs, aseptic meningitis, encephalopathy - ↑ LFTs, uric acid, LDH - Associated with rituximab (anti-CD20) & muromunab (anti-CD3) Adverse Reactions to Biologics • IL-2 (aldesleukin) - Capillary (vascular) leak syndrome - Uncommon but potentially fatal - Hypotension and edema due to extravascular fluid and protein extravasation Monoclonal Antibody Reactions • Anaphylaxis - Basiliximab (chimeric anti-IL2 receptor antagonist) - Muromonab (murine anti-CD3 mAb) - Cetuximab (anti-EGFR) : Due to pre-existing antibodies to an oligosaccharide, galactose-α-1,3-galactose present on the Fab portion of cetuximab (Chung NEJM 2008) : most had specific IgE to cetuximab before therapy Management of the Drug Allergic Patient • For most drugs no validated in vivo or in vitro diagnostic tests are available • If a patient requires a medication they are allergic to options include: 1) finding an alternative medication 2) performing a graded drug challenge 3) performing drug desensitization Drug Desensitization • Benefit - Established protocols for many drugs - Relatively safe : May be done in an office setting : Reactions during desensitization variable depending on drug but rarely severe • Disadvantages - Temporary effect (not tolerance induction) - Need to take medicine continuously to maintain desensitized state - Need to repeat for every subsequent courses Graded Challenge (Test Dose) • A graded challenge is a procedure to determine if a drug is safe to administer • Intended for patients who are unlikely to be allergic to the given drug • In contrast to a desensitization, a graded challenge does not modify the patient’s response to a drug Graded Challenge (Test Dose) • Benefit - Easy to perform - Typically start with 1/100th of final dose, then 1/10th and full dose - usually given every 30-60 minutes - confirms or negates drug allergy history • Disadvantages - Potentially higher risk Thank You!!!